Who is the manufacturer of Actifuse Flow?

Baxter Healthcare Corporation filed the 510(k) submission for Actifuse Flow (K181306).

What is the FDA product code for Actifuse Flow?

MQV. It is classified under 21 CFR 888.3045 as a Class 2 device in the Orthopedic panel.

What is the regulatory pathway for Actifuse Flow?

510(k) clearance (submission type: Special).

What are the predicate devices for Actifuse Flow?

Actifuse™ Flow Bone Graft Substitute (K082073).

Who can help prepare an FDA 510(k) submission like Actifuse Flow?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

Actifuse Flow

K181306 · Baxter Healthcare Corporation · MQV · Aug 17, 2018 · Orthopedic

Device Facts

Record ID	K181306
Device Name	Actifuse Flow
Applicant	Baxter Healthcare Corporation
Product Code	MQV · Orthopedic
Decision Date	Aug 17, 2018
Decision	SESE
Submission Type	Special
Regulation	21 CFR 888.3045
Device Class	Class 2
Attributes	Therapeutic

Intended Use

Actifuse™ Flow is a bone void filler intended only for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. Actifuse™ Flow can be injected into bony voids or gaps of the skeletal system, i.e., extremities, pelvis, and spine, including use in posterolateral spinal fusion procedures with appropriate stabilizing hardware. These defects may be surgically created osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by bone during process.

Device Story

Actifuse™ Flow is a resorbable, osteoconductive bone void filler composed of phase-pure silicon-substituted calcium phosphate granules in a resorbable polymer matrix. It mimics the porous structure of human cancellous bone. The device is supplied in a pre-filled applicator syringe for injection into bony voids or gaps. It is used by orthopedic surgeons in clinical settings to fill non-structural osseous defects. The material resorbs over time and is replaced by natural bone during the healing process. This submission covers modifications to the applicator syringe design and materials to create a ready-to-use delivery system.

Clinical Evidence

Bench testing only. No clinical data presented. Performance was assessed via chemical analysis to ensure modifications did not alter the product's structure or chemistry. Biocompatibility testing followed ISO 10993-1. Sterilization validated per ANSI/AAMI/ISO 11137-2. Shelf-life supported by aging testing.

Technological Characteristics

Phase-pure silicon-substituted calcium phosphate scaffold in resorbable polymer matrix. Interconnected porous structure. Delivered via syringe. Sterilized by radiation (SAL 10^-6). Biocompatibility per ISO 10993-1.

Indications for Use

Indicated for orthopedic patients requiring bone void filling in non-structural gaps/voids of the skeletal system (extremities, pelvis, spine), including posterolateral spinal fusion with stabilizing hardware. Applicable to surgically created or traumatic osseous defects.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Predicate Devices

Actifuse™ Flow Bone Graft Substitute (K082073)

Reference Devices

Actifuse™ Flow Bone Graft Substitute (K081979)
Altapore™ Bone Graft Substitute (K130531)
Actifuse™ ABX E-Z fil Putty Bone Graft Substitute (K071206)
Actifuse™ Bone Graft Substitute (K090850)

Related Devices

K082073 — ACTIFUSE FLOW BONE GRAFT SUBSTITUTE · Apatech , Ltd. · Sep 11, 2008
K080736 — ACTIFUSE SHAPE BONE GRAFT SUBSTITUTE · Apatech , Ltd. · Apr 16, 2008
K232315 — Catalyst Bone Void Filler · Ossdsign AB · Sep 15, 2023
K090731 — NOVABONE POROUS - SYNTHETIC BONE GRAFT SCAFFOLD · Novabone Products, LLC · Apr 15, 2009
K071206 — ACTIFUSE ABX E-Z-FIL PUTTY BONE GRAFT SUBSTITUTE · Apatech , Ltd. · May 31, 2007

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The FDA logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym with the full name of the agency on the right. The Department of Health & Human Services logo features a stylized human figure with three faces in profile, representing the department's focus on people's health and well-being. The FDA acronym is in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. August 17, 2018 Baxter Healthcare Corporation Daniel Davis Senior Manager, Global Regulatory Affairs 32650 North Wilson Road Round Lake, Illinois 60073 Re: K181306 Trade/Device Name: Actifuse™M Flow Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MOV Dated: July 18, 2018 Received: July 20, 2018 Dear Mr. Davis: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrl/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part {1}------------------------------------------------ 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Laurence D. Coyne -S For Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below. # Indications for Use 510(k) Number (if known) K181306 Device Name Actifuse TM Flow #### Indications for Use (Describe) Actifuse™ Flow is a bone void filler intended only for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. Actifuse™ Flow can be injected into bony voids or gaps of the skeletal system, i.e., extremities, pelvis, and spine, including use in posterolateral spinal fusion procedures with appropriate stabilizing hardware. These defects may be surgically created osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by bone during process. | Type of Use (Select one or both, as applicable) | | |------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------| | X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the word "Baxter" in a bold, blue font. The font appears to be sans-serif. The word is slightly italicized, giving it a sense of movement. # Section 5. 510(k) Summary May 22, 2018 #### OWNER: Baxter Healthcare Corporation One Baxter Parkway Deerfield, Illinois 60015 ## CONTACT PERSON: Daniel Davis Senior Manager, Global Regulatory Affairs 32650 N. Wilson Road Round Lake, IL 60073 Telephone: (224) 948-3775 Fax: (224) 270-4119 ### IDENTIFICATION OF THE DEVICE: Common Name: Filler, bone void, calcium compound Trade Name: Actifuse™ Flow Bone Graft Substitute Classification Panel: Orthopaedic and Rehabilitation Devices Panel Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler devices Regulatory Class: Class II Product Code: MQV | Model Number | Name | |--------------|--------------------------------------------| | 506005078076 | Actifuse Flow Bone Graft Substitute, 1.5ml | | 506005078077 | Actifuse Flow Bone Graft Substitute, 3.0ml | | 506005078078 | Actifuse Flow Bone Graft Substitute, 5.0ml | #### Table 1. Model Numbers for Actifuse™ Flow {4}------------------------------------------------ Image /page/4/Picture/1 description: The image shows the word "Baxter" in a bold, blue font. The letters are slightly italicized, giving the word a sense of movement. The font is sans-serif and appears to be a company logo. # PREDICATE DEVICE: # Table 2. Predicate Device | Device | Company | Predicate 510(k) | Clearance Date | |------------------------------------------|---------------------------------------------------------------------------------------------------|------------------|--------------------| | ActifuseTM Flow Bone Graft Substitute | ApaTech Limited 370 Centennial Avenue Elstree, Hertfordshire WD6 3TJ United Kingdom.1 | K082073 | September 11, 2008 | 1 ApaTech Limited was acquired by Baxter Healthcare Corporation in 2010 | Device | Company | Reference 510(k) | Clearance Date | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------|------------------| | Actifuse™ Flow Bone Graft Substitute, Actifuse™ Shape Bone Graft Substitute, Actifuse™ ABX E-Z fil Putty, Actifuse™ Bone Graft Substitute | ApaTech Limited 370 Centennial Avenue Elstree, Hertfordshire WD6 3TJ United Kingdom.1 | K081979 | November 6, 2008 | | Altapore™ Bone Graft Substitute | ApaTech Limited 370 Centennial Avenue Elstree, Hertfordshire WD6 3TJ United Kingdom.1 | K130531 | April 8, 2014 | | Actifuse™ ABX E-Z fil Putty Bone Graft Substitute | ApaTech Limited 370 Centennial Avenue Elstree, Hertfordshire WD6 3TJ United Kingdom.1 | K071206 | May 31, 2007 | | Actifuse™ Bone Graft Substitute Actifuse™ Microgranules Bone Graft Substitute Actifuse™ E-Z-Prep Actifuse™ ABX Bone Graft Substitute Actifuse™ MIS Actifuse™ Shape Bone Graft Substitute Actifuse™ Flow Bone Graft Substitute | ApaTech Limited 370 Centennial Avenue Elstree, Hertfordshire WD6 3TJ United Kingdom.1 | K090850 | July 30, 2009 | | 1 ApaTech Limited was acquired by Baxter Healthcare Corporation in 2010 | | | | # Table 3. Reference 510(k) {5}------------------------------------------------ Image /page/5/Picture/1 description: The image shows the word "Baxter" in a bold, blue font. The letters are slightly italicized, giving the word a sense of movement. The font is sans-serif and the color is a vibrant blue. ### DESCRIPTION OF THE DEVICE: Actifuse™ Flow Bone Graft Substitute is a bone void filler intended only for orthopaedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. Actifuse 11d Flow Bone Graft Substitute can be injected into bony voids or gaps of the skeletal system. i.e., extremities, pelvis, and spine, including use in posterolateral spinal fusion procedures with appropriate stabilizing hardware. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by bone during the healing process. Actifuse™ Flow is phase-pure silicon-substituted calcium phosphate osteoconductive bone void filler, comprising a single-phase calcium phosphate scaffold delivered in a matrix of resorbable polymer. The interconnected and open porous structure inherent of the source material for the mineral phase of Actifuse™ Flow is similar to human cancellous bone. ## INDICATIONS FOR USE: Actifuse™ Flow is a bone void filler intended only for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. Actifuse™ Flow can be injected into bony voids or gaps of the skeletal system, i.e., extremities, pelvis, and spine, including use in posterolateral spinal fusion procedures with appropriate stabilizing hardware. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by bone during the healing process. ### PURPOSE OF SUBMISSION: The basis for this premarket notification is modifications to the Actifuse™ Flow product line. The modifications consist of applicator syringe design changes (both material and dimensional changes) to create a ready-to-use version of the Actifuse™ Flow device. The proposed new applicator syringe materials are currently used in Baxter's Altapore and Actifuse™ ABX Bone Graft substitute product lines and have been previously cleared under 510(k) premarket notifications K130531 (cleared date 8th Apr, 2014) and K071206 (cleared date 31st May, 2007) respectively. The hydroxyapatite granules used in Actifuse ABX. Actifuse Flow, and Altapore are all chemically identical. These modifications do not impact the intended use or the fundamental technology of the devices. {6}------------------------------------------------ Image /page/6/Picture/1 description: The image shows the word "Baxter" in a bold, blue font. The font appears to be sans-serif and slightly italicized. The word is the main focus of the image and is positioned horizontally. ## TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE: The proposed devices have equivalent technological characteristics as Baxter's currently cleared Actifuse™ Flow product line, cleared under 510(k) premarket notification K082073 (cleared September 11, 2008). ## DISCUSSION OF NON-CLINICAL DATA: Baxter Healthcare Corporation conducts risk analyses and design verification tests based on the result of these analyses. All test results meet the acceptance criteria, and support that the proposed devices are appropriately designed for their intended use. All testing was performed on the configuration of the devices presented in this premarket notification. ### Performance Data The performance of the Actifuse™ Flow device after modifications made to the applicator syringe was assessed by analyzing the Actifuse™ Flow final product for chemical changes relative to the predicate product's specification. All testing confirmed that the modifications had no impact to the chemistry or structure of the Actifuse™ Flow product. #### Biocompatibility All materials found in these devices that are the subject of this submission have been previously cleared under Baxter's 510(k) premarket notifications K082073 (clearance date September 11, 2008), K130531 (clearance date April 8, 2014) and K071206 (clearance date 31st May, 2007). Biocompatibility assessments were conducted based on ISO-10993-1, Biological Evaluation of Medical Devices for permanent duration, implant device, tissue/bone contact, and FDA Guidance, Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process", as recommended in the "Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device: Guidance for Industry and FDA". #### Sterility The Actifuse The Flow product line is sterilized with radiation. The minimum sterilizing dose (MSD) required to provide a 10-6 Sterility Assurance Level (SAL) for this (sub) category was established and validated at the manufacturing facility as described in {7}------------------------------------------------ Image /page/7/Picture/1 description: The image shows the word "Baxter" in a bold, blue font. The font appears to be sans-serif and slightly italicized. The word is the main focus of the image and is positioned horizontally. ANSI/AAMI/ISO ISO 11137-2, "Sterilization of health care products- Radiation-Part 2: Establishing the Sterilization Dose." These products are labeled "Sterile". Package Verification testing is based on Visual Inspection, Seal Strength, and Bubble Leak testing. ### Shelf Life Baxter has performed aging testing to support a shelf-life claim of two (2) years. ### CONCLUSION: Actifuse™ Flow Bone Graft Substitute is as safe and effective as the predicate Actifuse™ Flow Bone Graft Substitute. Both devices share indications for use, technological characteristics, and principles of operation. The only differences between the two devices are the changes to the dimensions and materials of the syringes housing the devices. The non-clinical data demonstrate that the subject device is substantially equivalent and performs comparably to the predicate device.